CN106661121A - 经修饰的抗原结合多肽构建体及其用途 - Google Patents

经修饰的抗原结合多肽构建体及其用途 Download PDF

Info

Publication number
CN106661121A
CN106661121A CN201580036617.1A CN201580036617A CN106661121A CN 106661121 A CN106661121 A CN 106661121A CN 201580036617 A CN201580036617 A CN 201580036617A CN 106661121 A CN106661121 A CN 106661121A
Authority
CN
China
Prior art keywords
amino acid
acid modifications
heterodimer
construct
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580036617.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·桑彻斯
T·斯普雷特冯克罗登斯泰恩
D·厄洛塞夫
S·A·L·汤姆-耶
A·L·科珀
I·E·P·德安杰罗
Y-C·周
S·B·迪克西特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymeworks BC Inc
Original Assignee
Zymeworks BC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks BC Inc filed Critical Zymeworks BC Inc
Priority claimed from PCT/IB2015/054107 external-priority patent/WO2015181805A1/en
Publication of CN106661121A publication Critical patent/CN106661121A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580036617.1A 2015-04-28 2015-05-29 经修饰的抗原结合多肽构建体及其用途 Pending CN106661121A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154055P 2015-04-28 2015-04-28
US62/154,055 2015-04-28
PCT/IB2015/054107 WO2015181805A1 (en) 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof

Publications (1)

Publication Number Publication Date
CN106661121A true CN106661121A (zh) 2017-05-10

Family

ID=58848603

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580036617.1A Pending CN106661121A (zh) 2015-04-28 2015-05-29 经修饰的抗原结合多肽构建体及其用途

Country Status (3)

Country Link
JP (4) JP7103751B6 (https=)
KR (2) KR102669686B1 (https=)
CN (1) CN106661121A (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823167A (zh) * 2018-09-07 2021-05-18 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
CN114106192A (zh) * 2021-12-20 2022-03-01 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2022223016A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
US12060436B2 (en) 2012-11-28 2024-08-13 Zymeworks Bc Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
JP7535273B2 (ja) * 2019-04-26 2024-08-16 スアンズ バイオファーマシューティカル カンパニー，リミテッド Ｃｄ８０バリアントタンパク質とその使用
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
JP2024544607A (ja) * 2021-11-25 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー 少量の抗体副産物の定量

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269466A1 (en) * 2005-07-19 2008-10-30 Ucb Pharma S.A. Modified Antibody Fragments
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2014018572A2 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
CN103608357A (zh) * 2011-03-25 2014-02-26 格兰马克药品股份有限公司 异二聚体免疫球蛋白
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN104114579A (zh) * 2011-10-27 2014-10-22 根马布股份公司 异二聚体蛋白的生成
CN104163864A (zh) * 2007-03-30 2014-11-26 Ambrx公司 经修饰fgf-21多肽和其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2786762T3 (da) * 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA3244731A1 (en) * 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269466A1 (en) * 2005-07-19 2008-10-30 Ucb Pharma S.A. Modified Antibody Fragments
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CN104163864A (zh) * 2007-03-30 2014-11-26 Ambrx公司 经修饰fgf-21多肽和其用途
CN103608357A (zh) * 2011-03-25 2014-02-26 格兰马克药品股份有限公司 异二聚体免疫球蛋白
CN104114579A (zh) * 2011-10-27 2014-10-22 根马布股份公司 异二聚体蛋白的生成
WO2014018572A2 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN KLEIN ET AL.: "Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies", 《LANDES BIOSCIENCE》, vol. 4, no. 6, 31 December 2012 (2012-12-31), pages 653 - 663 *
STEVEN M LEWIS ET AL.: "Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface", 《NATURE BIOTECHOLOGY》, vol. 32, no. 2, 26 January 2014 (2014-01-26), pages 191 - 198 *
T. SPRETER VON KREUDENSTEIN ET AL.: "Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering", 《METHODS》, vol. 65, 6 November 2013 (2013-11-06), pages 77 - 94 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060436B2 (en) 2012-11-28 2024-08-13 Zymeworks Bc Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN112823167A (zh) * 2018-09-07 2021-05-18 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
CN112823167B (zh) * 2018-09-07 2025-07-15 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
WO2022223016A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
CN114106192A (zh) * 2021-12-20 2022-03-01 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2023116099A1 (zh) * 2021-12-20 2023-06-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Also Published As

Publication number Publication date
JP7103751B2 (ja) 2022-07-20
KR20230019503A (ko) 2023-02-08
JP7183221B2 (ja) 2022-12-05
JP2020202848A (ja) 2020-12-24
JP2024125389A (ja) 2024-09-18
KR20240093883A (ko) 2024-06-24
KR102669686B1 (ko) 2024-05-29
JP7103751B6 (ja) 2022-08-15
JP2023027107A (ja) 2023-03-01
JP2018502550A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
US12286489B2 (en) Modified antigen binding polypeptide constructs and uses thereof
JP7080955B2 (ja) 遺伝子操作された免疫グロブリン重鎖－軽鎖対およびその使用
JP2024125389A (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
RU2826203C1 (ru) Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение
HK40077442A (en) Modified antigen binding polypeptide constructs and uses thereof
HK1237351A1 (en) Modified antigen binding polypeptide constructs and uses thereof
HK40121605A (zh) 工程化免疫球蛋白重链-轻链对及其用途
HK40121604A (zh) 工程化免疫球蛋白重链-轻链对及其用途
HK1216899B (zh) 工程化免疫球蛋白重链-轻链对及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237351

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: British Columbia

Applicant after: Yeast Biopharmaceutical Co.,Ltd.

Address before: British Columbia

Applicant before: ZYMEWORKS Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: British Columbia

Applicant after: Enzymatic British Columbia Ltd.

Address before: British Columbia

Applicant before: Yeast Biopharmaceutical Co.,Ltd.